LncRNA MT1JP Plays a Protective Role in Cholangiocarcinoma by Regulating miR-18a-5p/FBP1 Axie

Wei Zhao (✉ zhaoweiqdyf@126.com)
Department of Hepatopancreatobilary Surgery, The Affiliated Hospital of Qingdao University, Qingdao 266000, People's Republic of China
https://orcid.org/0000-0003-2549-8063

Jing Zhao
Qingdao Women and Childrens Hospital

Xiao Guo
Qingdao Fuwai Cardiovascular Hospital

Yujie Feng
the Affiliated hospital of Qingdao University

Bingyuan Zhang
the Affiliated hospital of Qingdao University

Lantian Tian
the Affiliated hospital of Qingdao University

Research article

Keywords: IncRNA, MT1JP, cholangiocarcinoma, miRNA, tumor

DOI: https://doi.org/10.21203/rs.3.rs-42881/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background: Cholangiocarcinoma is a common malignant tumor of digestive system. LncRNA MT1JP has been reported to play tumor-suppressing roles in multiple cancers. However, the effect of MT1JP on cholangiocarcinoma has not been evaluated.

Methods: The expression of MT1JP in cholangiocarcinoma specimens and paired para-carcinoma tissues were detected by real-time PCR. The overexpression plasmid and siRNA of MT1JP were transfected into cholangiocarcinoma cells to change the expression levels of MT1JP. CCK-8, flow cytometry and transwell assays were performed to measure proliferation, cell cycle transition, apoptosis, migration and invasion in cholangiocarcinoma cells. Dual-luciferase reporter assay, real-time PCR and western blot were carried out to screen the miRNA bound by MT1JP. In addition, xenograft experiment was used to determine the tumorigenesis of cholangiocarcinoma cells in nude.

Results: MT1JP was downregulated in cholangiocarcinoma specimens, compared with para-carcinoma tissues, and its expression was related with tumor size, TNM stage and lymph node metastasis. Overexpression of MT1JP inhibited proliferation, cell cycle transition, migration and invasion, and induced apoptosis in cholangiocarcinoma cells. The knockdown of MT1JP led to opposite results. MT1JP bound to miR-18a-5p to facilitate the expression of fructose-1,6-bisphosphatase 1 (FBP1). MiR-18a-5p was increased in cholangiocarcinoma samples, and its expression was negatively correlated with that of MT1JP. In addition, MT1JP also suppressed tumorigenesis in nude mice.

Conclusions: MT1JP alleviated proliferation, migration and invasion, and induced apoptosis in cholangiocarcinoma cells by regulating miR-18a-5p/FBP1 axis. These findings may provide novel insights for diagnosis and treatment of cholangiocarcinoma in clinic.

Background

Cholangiocarcinoma is a common malignant tumor of digestive system, and the overall incidence of cholangiocarcinoma has progressively increased worldwide over the past decades [1]. Based on anatomical location, cholangiocarcinoma is classified into intrahepatic, perihilar and distal cholangiocarcinoma [2]. The incidence of cholangiocarcinoma varies in different parts of the world. In Southeast Asia the morbidity of cholangiocarcinoma is as high as 113/100,000 in men and 50/100,000 in women, while in western countries the incidence is low at 0.2/100,000 in men and 0.1/100,000 in women [3, 4]. At present, surgery resection is still the only effective treatment for cholangiocarcinoma. As the anatomical concealment of bile duct, most patients with early stage are asymptomatic, and the early diagnose is difficult [5]. Most patients are diagnosed at an advanced stage with metastasis [6]. For patients with advanced-stage or unresectable cholangiocarcinoma, the available systemic therapies are of limited effectiveness: the median overall survival with the current standard-of-care chemotherapy regimen is less than one year [7]. Therefore, the early diagnosis is vital for outcome of cholangiocarcinoma patients.
Long noncoding RNAs (lncRNAs) are a group of noncoding RNAs with length of more than 200 nucleotides. LncRNAs have been known abundant in lives, and to widely regulate gene expression via various ways [8, 9]. LncRNA metallothionein 1J pseudogene (MT1JP) was first reported as a tumor suppressor in liver cancer cells by regulating the translation of p53 [10]. Subsequently, MT1JP was found as a ceRNA to bind to miR-214-3p to facilitate runt related transcription factor 3 (RUNX3) expression, and suppressed cell proliferation, invasion and migration in gastric cancer cells [11]. The tumor-suppressing role of MT1JP has been verified in multiple cancer types, but its effect on cholangiocarcinoma has not been evaluated.

In our previous study, MT1JP was found downregulated in cholangiocarcinoma specimens, compared with paired para-carcinoma tissues. In addition, MT1JP was predicted to bind to miR-18a-5p seed sequence. In the present study, the effect of MT1JP on cholangiocarcinoma cells was investigated via gain- and loss-of-function experiments, and the relation between MT1JP and miR-18a-5p was also studied.

**Methods**

**Clinical specimens**

Thirty paired of cholangiocarcinoma and para-carcinoma tissues were collected from January 2016 to December 2019 in hepatological surgery department, affiliated hospital of Qingdao University via surgery resection. The patients had not received chemotherapy or radiotherapy treatment. The specimens were identified as cholangiocarcinoma by pathological examination. Informed consent was obtained from each patient. The specimen collection and experimental procedure were line with Declaration of Helsinki, and approved by Ethics Committee of Affiliated Hospital of Qingdao University.

The expression levels of MT1JP and miR-18a-5p in the cholangiocarcinoma specimens were detected with real-time PCR.

The expression level of MT1JP in another 58 cholangiocarcinoma samples was analyzed with the patients’ clinical pathological characteristics by Chi-square test.

**Real-time PCR**

Total RNA was extracted with TRIpure reagent (BioTeke, Beijing, China), and reversely transcribed into cDNA with M-MLV reverse transcriptase (BioTeke), in presence of Olig(dT) and random, or specific miRNA primers (GenScript, Nanjing, China). The cDNA was used for real-time PCR to detect the expression levels of MT1JP and miR-18a-5p, and mRNA level of FBP1 with 2×Power Taq PCR MasterMix (BioTeke) and SYBR Green (Sigma, St. Louis, USA). The data were analyzed using $2^{-\Delta\Delta Ct}$ method. β-actin served as the internal control of MT1JP, and 5S served as the internal control of miR-18a-5p. The sequence information of primers was shown in Table 1.
Western blot

The protein was extracted using lysis buffer supplemented with 1 mM PMSF (Beyotime, Haimen, China), and the concentration was determined with BCA protein assay kit (Beyotime). Then the protein was separated with SDS-PAGE, and transferred onto polyvinylidene difluoride membrane (Millipore, Boston, USA). The membrane was blocked with skim milk (YILI, Hohhot, Inner Mongolia, China) at room temperature for 1 h, and incubated with following antibodies at 4 °C overnight: rabbit anti-proliferating cell nuclear antigen (PCNA) (1:1000; cat. no. A0264, Abclonal, Wuhan, Hubei, China), rabbit anti-caspase-3 (1:1000; cat. no. A19654, Abclonal), rabbit anti-poly ADP-ribose polymerase (PARP) (1:1000; cat. no. A0942, Abclonal), rabbit anti-cyclin E (1:1000; cat. no. AF0144, Affinity, Changzhou, Jiangsu, China), rabbit anti-cyclin B1 (1:1000; cat. no. A2056, Abclonal), rabbit anti-fructose-1,6-bisphosphatase 1 (FBP1) (1:5000; cat. no. 12842-1-AP, Proteintech, Wuhan, Hubei, China) or mouse anti-β-actin (1:1000; cat. no. sc-47778, Santa Cruz, USA). After rinsing with TBST, the membrane was incubated with goat anti-rabbit or mouse secondary antibody (1:5000; cat. no. A0208, A0216, Beyotime) at 37 °C for 45 min. The protein in the membrane was reacted with ECL reagent (Beyotime), followed with a signal exposure in the dark. The optical density of the blotting bands was analyzed with Gel-Pro-Analyzer software.

Cell culture

Cholangiocarcinoma cell lines HCCC-9810 and RBE were purchased from Procell (Wuhan, China), and HUCCT1 from Zhongqiaoxinzhou (Shanghai, China). The cells were cultured in RPMI-1640 medium (Gibco BRL, Gaithersburg, USA) supplemented with 10% fetal bovine serum (FBS) (Hyclone, Logan, USA) at 37 °C with 5% CO₂.

Cell transfection was performed with Lipofectamine 2000 reagent (Invitrogen, Carlsbad, USA) in serum-free medium according to the manufacturer's protocol.

To obtain the stably transfected cell line, HCCC-9810 cells were transfected with MT1JP overexpression plasmid, and treated with 400 μg/ml G418 for 2 weeks. The single cells were selected out, and cultured without G418. After verification of MT1JP in RNA levels, the MT1JP-stably expressed cell lines were obtained.

Cell counting kit-8 (CCK-8) assay

CCK-8 assay was performed to measure the cell viability. The cells were cultured in 96-well plates at 37 °C with 5% CO₂. After culture for 0 h, 24 h, 48 h or 72 h, the cells were incubated with CCK-8 reagent (10 μl per well) (KeyGEN, Nanjing, China) for 2 h. The optical density of medium was detected with a microplate reader (BioTek, Winooski, VT, USA) at 450 nm.

Flow cytometry

Flow cytometry was used for detection of apoptosis and cell cycle.
The cells were collected, and incubated with Annextin V-FITC reagent and propidium iodide at room temperature for 20 min in the dark. Then the cells were detected by flow cytometer (BD, Franklin Lakes, NJ, USA).

For cell cycle detection, the cells were collected and immobilized with 70% ethanol at 4 °C overnight. Then the cells were incubated with PI/RNaseA buffer at room temperature for 60 min in the dark, and used for detection by flow cytometer.

**Transwell assay**

Transwell assay was used for detection of migration and invasion.

The cells were collected and counted. About 3×10^3 cells were seeded into the upper chamber with serum-free medium, and the lower chamber was added with medium with 30% FBS. After culture for 24 h, the cells on the reverse surface of transwell membrane was fixed with 4% paraformaldehyde (Aladdin, Shanghai, China) and stained with 0.4% crystal violet (Amresco, Solon, OH, USA). The cells were photographed and counted under a microscope at 100× magnification.

For invasion analysis, the polycarbonate membrane of transwell chambers (Corning, NY, USA) was pre-coated with Matrigel at 37 °C. Approximately 1.5×10^4 cells were seeded into upper chamber with serum-free medium, and medium with 30% FBS were added into the lower chamber. After culture for 24 h, the cells on the reverse surface was fixed and stained, and the cell number was counted under a microscope.

**Dual-luciferase assay**

The binding between MT1JP and miR-18a-5p was analyzed by bioinformatic website RNAhybrid (https://bibiserv.cnb.bielefeld.de/rnahybrid/). The MT1JP sequence containing miR-18a-5p-bound region or mutant sequence was cloned into pmirGLO vector with *NheI* and *XhoI* sites, and cotransfected into 293T cells with miR-18a-5p mimics. Twenty-four hours later, the cells were lysed, and the luciferase activity of pmirGLO vector was detected.

The candidate targets of miR-18a-5p were predicted by bioinformatic website targetscan (http://www.targetscan.org/vert_71/). The 3’ untranslation region (UTR) sequence of FBP1 containing miR-18a-5p-bound region or its mutant sequence was synthesized and inserted into pmirGLO vector with *NheI* and *XhoI* sites. 293T cells were cotransfected with pmirGLO vector and miR-18a-5p mimics, and the activity of luciferase activity was determined.

**Immunofluorescent staining**

The cells were pre-seeded on glass slides. After culture for certain times, the cells were fixed with 4% paraformaldehyde for 15 min, permeated with 0.1% TritonX-100 (Beyotime) for 30 min, and blocked with goat serum for 10 min at room temperature. Subsequently, the cells were incubated with antibody against FBP1 (1:100; cat. no. 12842-1-AP, Proteintech) at 4 °C overnight, incubated with secondary antibody
labeled with Cy3 (1:200; cat. no. A0516, Beyotime) at room temperature in the dark for 60 min, and counterstained with DAPI (Aladdin). Finally, the glass slide were mounted with anti-fading reagent (Solarbio, Beijing, China), and the cells were observed under a fluorescent microscope (Olympus, Tokyo, Japan) at 400× magnification.

**Xneograft model**

Healthy BALB/c mice were purchased from HFK Biotechnology Co. Ltd. (Beijing, China), and kept in a controlled environment (12 h/12 h light/dark, 22±1 ℃) with free access to food and water. The animals were taken care of according to Guide for the Care and Use of Laboratory animal (8th edition, NIH), and the experimental procedures were approved by Ethics Committee of Affiliated Hospital of Qingdao University.

After accommodation for one week, the mice were subcutaneously injected with HCCC-9810 cells (5×10^5 each mouse) stably transfected with MT1JP overexpression plasmid or pcDNA3.1 vector. One week later, the tumor size was measured every 3 days. Three weeks after injection, the mice were euthanized via overdose of pentobarbital sodium (200 mg/kg, intraperitoneal injection), and the tumors were isolated for detection.

**HE staining**

The tumor isolated from mice were fixed in 4% paraformaldehyde overnight, and washed with flow water for 4 h. Then the tissue was dehydrated with ethanol of grading concentrations and xylene, embedded with paraffin, and cut into sections of 5 μm. The sections were deparaffinized with xylene and ethanol, and stained with hematoxylin (Solarbio). After soaking in 1% hydrochloric acid/ethanol for several seconds, the sections were stained with eosin (Sangon, Shanghai, China). Finally, the sections were dehydrated again, mounted with gum, and observed under a microscope at 200× magnification.

**TUNEL staining**

The tumor tissue was made into paraffin sections as described previously. After deparaffinization, the sections were permeated with 0.1% Triton X-100, and blocked with 3% H₂O₂ at room temperature. Then the sections were incubated with TUNEL buffer (Roche, Basel, Switzerland) for 60 min at 37 ℃ in the dark, and incubated with Converter-POD reagent for 30 min at 37 ℃. Subsequently, the sections were reacted with DAB substrate (Solarbio), and counterstained with hematoxylin. Finally, the sections were dehydrated, mounted and photographed with a microscope at 400× magnification.

**Immunohistochemical staining**

The tumor tissues were used for immunohistochemical staining for detection of Ki-67 and FBP1. The tissues were made into sections as previous description. The sections were reacted with antigen repair buffer in boiling for 10 min, and blocked with 3% H₂O₂ and goat serum. Then the section were incubated with antibody against Ki-67 (1:100; cat. no. AF0198, Affinity) or FBP1 (1:100; cat. no. 12842-1-AP,
Proteintech) at 4 °C overnight. After washing with PBS, the sections were incubated with secondary antibody labeled with HRP (1:500; Beyotime) at 37 °C for 60 min, and reacted with DAB substrate. After counterstaining with hematoxylin, the sections were dehydrated, mounted and observed with a microscope at 400× magnification.

**Statistical analysis**

The data in this study were presented as mean±SD, and analyzed with GraphPad Prism 8.0. The data from two independent groups were analyzed with student’s t test. Comparisons among multiple groups were performed with one-way or two-way analysis of variance followed with Bonferroni post-hoc test. The correlation between MT1JP and clinical features were analyzed by Pearson χ² test. The correlation between MT1JP and miR-18a-5p was analyzed with Pearson test. A p value less than 0.05 was considered as statistically significantly.

**Results**

**MT1JP was downregulated in cholangiocarcinoma specimens**

The expression of MT1JP in cholangiocarcinoma tissues were detected by real-time PCR. As shown in Fig. 1A, the MT1JP was downregulated in cholangiocarcinoma tissues, compared with para-carcinoma tissues. On the contrary, the expression of miR-18a-5p was increased in cholangiocarcinoma samples (Fig. 1B). In addition, the correlation between MT1JP and miR-18a-5p was analyzed with pearson test, and Fig. 1C revealed that the expression of MT1JP was negatively related with that of miR-18a-5p.

Next, the correlation between MT1JP expression and clinicopathological characteristics were analyzed. As shown in Table 2, the expression level of MT1JP was significantly related with tumor size, TNM stage and lymph node metastasis.

**MT1JP inhibited proliferation and promoted apoptosis in cholangiocarcinoma cells**

As MT1JP was decreased in cholangiocarcinoma tissues, its expression was examined in several cholangiocarcinoma cell lines. As shown in Fig. 2A, MT1JP was lowest expressed in HCCC-9810 cells, and highest expressed in HUCCT1 cells, which was opposite with that of miR-18a-5p (Fig. 2B). In order to investigate the roles of MT1JP in cholangiocarcinoma cells, MT1JP overexpression plasmid was transfected into MT1JP low-expressed HCCC-9810 cells, and its siRNA was transfected into high-expressed HUCCT1 cells. The effectiveness of overexpression and silencing was confirmed by real-time PCR (Fig. 2C).

Next, the proliferation and apoptosis was detected. CCK-8 assay showed that MT1JP inhibited cell ability in cholangiocarcinoma cells (Fig. 2D and 2E). The expression level of PCNA was decreased after MT1JP overexpression and increased after MT1JP knockdown (Fig. 2F). The flow cytometry results revealed that MT1JP delayed G1/S and S/G2 transition in HCCC-9810 cells, and the silencing of MT1JP accelerated
cell cycle transition in HUCCT1 cells (Fig. 2G), which was supported by expression of cyclin B1 and cyclin E (Fig. 2H). In addition, the ectopic expression of MT1JP enhanced apoptosis in HCCC-9810 cells, evidenced by expression changes of cleaved caspase-3 and cleaved PARP (Fig. 2I and 2J). The knockdown slightly inhibited the apoptosis in HUCCT1 cells (Fig. 2I).

**MT1JP suppressed migration and invasion in cholangiocarcinoma cells**

Next, the migration and invasion ability of cholangiocarcinoma cells were determined by transwell assay with or without Matrigel. As shown in Fig 3, the overexpression of MT1JP suppressed migration and invasion in HCCC-9810 cells, and the silencing of MT1JP enhanced migration and invasion in HUCCT1 cells.

**MT1JP bound to miR-18a-5p as a sponge and regulated the expression of FBP1**

As the negative relation between MT1JP and miR-18a-5p expression levels, the correlation between MT1JP and miR-18a-5p was detected. The bioinformatic website RNAhybrid (https://bibiserv.cebitec.uni-bielefeld.de/rnahybrid/) predicted two binding sites between MT1JP and miR-18a-5p (Fig. 4A). Dual-luciferase reporter assay revealed that miR-18a-5p decreased the luciferase activity of dual-luciferase reporter containing MT1JP site-1 and site-2, not their mutant sites (Fig. 4B), and MT1JP negatively regulated the expression of miR-18a-5p (Fig. 4C). In addition, FBP1 was predicted as a candidate target of miR-18a-5p, and the miR-18a-5p can bind to the 3'UTR of FBP1 (Fig. 4A). Dual-luciferase reporter assay verified the binding of miR-18a-5p to FBP1-3'UTR (Fig. 4D), and western blot demonstrated that the expression levels of FBP1 was declined after transfection of miR-18a-5p mimics (Fig. 4E). Therefore, we hypothesized that MT1JP regulated expression of FBP1 by sponging miR-18a-5p. To confirm the hypothesis, the expression of FBP1 was examined after overexpression of MT1JP and miR-18a-5p. As shown in Fig. 4F, the expression of FBP1 was increased after ectopic expression of miR-18a-5p, which was reversed after transfection of miR-18a-5p mimics (Fig. 4F), suggested that MT1JP competitively bound to miR-18a-5p with FBP1. The immunohistochemical staining confirmed that MT1JP suppressed the expression of FBP1 (Fig. 4G).

**The effect of MT1JP was attenuated by overexpression of miR-18a-5p or knockdown of FBP1**

In order to further investigate the mechanism of MT1JP function, the MT1JP overexpression plasmid was cotransfected with miR-18a-5p or FBP1 siRNA. As shown in Fig. 5, increase of cell viability and invade ability and the decrease of apoptosis of induced by MT1JP was abolished by transfection of miR-18a-5p mimics in HCCC-9810 cells (Fig. 5A-C). Similarly, the effect of MT1JP on cell viability, apoptosis and invasion in HCCC-9810 cells were attenuated by FBP1 siRNA (Fig. 5D-F). These results demonstrated that MT1JP played its role by binding to miR-18a-5p and facilitated the expression of FBP1.

**MT1JP restrained tumorigenesis in nude mice**

To investigate the effect of MT1JP on tumorigenesis of cholangiocarcinoma cells, the HCCC-9810 cells with stable expression of MT1JP were subcutaneously injected into nude mice (n=6). The tumors were
isolated 3 weeks after injection. Fig. 6A and 6B showed that MT1JP significantly inhibited tumorigenesis in nude mice. HE staining, TUNEL and immunohistochemical staining of Ki-67 revealed that MT1JP led to cell necrosis and apoptosis, and suppressed cell proliferation in tumors (Fig. 6C-E). The real-time PCR and immunohistochemical staining results demonstrated that in MT1JP-overexpressed tumors, the expression of miR-18a-5p was declined, and that of FBP1 was elevated (Fig. 6F-G), which supported the hypothesis that MT1JP bound to miR-18a-5p and facilitated the expression of FBP1.

**Discussion**

In this study, we found that MT1JP was downregulated in clinical cholangiocarcinoma specimens, and its expression was correlated with tumor size, TNM stage and lymph node metastasis. Gain- and loss-of-function experiments demonstrated that MT1JP inhibited cell proliferation, cell cycle transition, migration and invasion, and promoted apoptosis in cholangiocarcinoma cells. Xenograft experiments showed that MT1JP suppressed tumorigenesis in nude mice. In addition, miR-18a-5p was increased in cholangiocarcinoma tissues, which was negatively correlated with that of MT1JP. MT1JP bound to miR-18a-5p as a sponge, and enhanced the expression of a target of miR-18a-5p, FBP1.

The tumor-suppressing role of MT1JP has been reported in multiple cancer cells, including breast cancer, glioblastoma, bladder cancer and gastric cancer [11-14]. The expression of lncRNA is often tissue-specific. We first demonstrated its effect on cholangiocarcinoma cells. The *MT1JP* gene locates in chromosome 16 in a cluster consisting of several homologous protein-coding genes of the metallothionein family [10]. MT1JP has been known to bind to miRNAs to play its roles. In this study, we demonstrated that MT1JP bound to miR-18a-5p to facilitate the expression of FBP1. MiR-18a-5p belongs to miR-17-92 cluster, plays tumor-promoting roles in colorectal cancer, lung cancer and renal cell carcinoma cells [15-17]. However, one study reported that miR-18a-5p was downregulated in breast cancer tissues, and inhibited migration and invasion in breast cancer cells [18]. These reporters suggested that the role of miR-18a-5p may be different in various cancers. In our study, miR-18a-5p was increased in cholangiocarcinoma specimens, and its overexpression enhanced proliferation and invasion, and reduced apoptosis in cholangiocarcinoma cells. FBP1 was confirmed as a target of miR-18a-5p. FBP1 is gluconeogenesis regulatory enzyme, and catalyzes the hydrolysis of fructose-1,6-bisphosphate to fructose-6-phosphate and inorganic phosphate [19]. In our previous study, FBP1 was demonstrated to inhibit proliferation and metastasis in cholangiocarcinoma cells by regulating Wnt/β-catenin signaling pathway [20]. MT1JP may function via miR-18a-5p/FBP1/Wnt/β-catenin axis.

In this study, we analyzed the correlation between MT1JP expression and clinical characteristics of 58 cholangiocarcinoma patients, and found that the expression level of MT1JP was related with tumor size, TNM stage and lymph node metastasis. The MT1JP low expression is more common in patients with larger tumor, advanced stage or/and existence of lymph node metastasis. Moreover, the expression of MT1JP was significantly decreased in cholangiocarcinoma samples. These finding suggested that MT1JP may participate in proliferation and metastasis of cholangiocarcinoma cells. Unlimited growth and metastasis are most important and terrible characteristics of malignant tumors. The malignant
behaviors of cancer cells contain excessive proliferation, reduced apoptosis, unusual migratory and invade abilities and so on. The three cell lines, HCCC-9810, RBE and HUCCT1, are isolated from intrahepatic cholangiocarcinoma tissues, and present as epithelial cells [21-23]. Overexpression of MT1JP inhibited proliferation and cell cycle transition, and induced apoptosis in HCCC-9810 cells, evidenced by the decreased expression level of PCNA, cyclin B1, cyclin E, and increased expression level of cleaved caspase-3 and PARP. Migratory and invade abilities were also reduced after ectopic expression of MT1JP. Opposite results were observed in MT1JP-silenced HUCCT1 cells. These results were consistent with previous papers about MT1JP in other cancers.

We came up with a hypothesis that MT1JP acted as a miRNA sponge, and bound to miR-18a-5p. In our results, the miR-18a-5p level was inhibited by MT1JP, suggested that MT1JP may be a degradable sponge. The expression of FBP1 was inhibited by miR-18a-5p, but enhanced by MT1JP, suggested that MT1JP competed with FBP1 for binding to miR-18a-5p. This hypothesis needs to be supported by more experiment results.

Conclusions

In this study, we demonstrated that IncRNA MT1JP was downregulated in cholangiocarcinoma tissues. MT1JP inhibited proliferation, migration, invasion and tumorigenesis and enhanced apoptosis in cholangiocarcinoma cells as a miRNA sponge to bind to miR-18a-5p to facilitate the expression of FBP1. These findings may provide novel diagnostic and therapeutic targets.

Abbreviations

MT1JP, metallothionein 1J pseudogene; FBP1, fructose-1,6-bisphosphatase 1; IncRNA, long noncoding RNA; PCNA, anti-proliferating cell nuclear antigen; PARP, anti-poly ADP-ribose polymerase; TUNEL, terminal deoxynucleoitidyl transferase mediated nick end labeling; TNM stage, tumor-node-metastasis stage.

Declarations

Ethics approval and consent to participate

All patients that participated to this study provided informed writing consent. This study was approved by Ethic Committee of affiliated hospital of Qingdao University.

Consent for publication

Not applicable.

Availability of data and materials

The data in this study will not be shared due to the policy of the Ethic Committee.
Competing interest

The authors declare that there is no conflict of interest.

Funding

Not applicable.

Author contribution

WZ designed the study. JZ, XG, YJ, BY and LT performed experiments and analyzed data. WZ drafted the manuscript. The submission was approved by all authors.

Acknowledgments

Authors are particularly grateful to the affiliated hospital of Qingdao University for providing laboratory, instruments and materials for this study.

References

1. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC: Changing international trends in mortality rates for liver, biliary and pancreatic tumours. Journal of hepatology 2002, 37(6):806-813.

2. Razumilava N, Gores GJ: Cholangiocarcinoma. Lancet 2014, 383(9935):2168-2179.

3. Blechacz BR, Gores GJ: Cholangiocarcinoma. Clinics in liver disease 2008, 12(1):131-150, ix.

4. Tyson GL, El-Serag HB: Risk factors for cholangiocarcinoma. Hepatology 2011, 54(1):173-184.

5. Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ: Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nature reviews Clinical oncology 2018, 15(2):95-111.

6. Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BJ, Youssef BM, Klimstra D, Blumgart LH: Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Annals of surgery 2001, 234(4):507-517; discussion 517-509.

7. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. The New England journal of medicine 2010, 362(14):1273-1281.

8. Quinn JJ, Chang HY: Unique features of long non-coding RNA biogenesis and function. Nature reviews Genetics 2016, 17(1):47-62.
9. Thomson DW, Dinger ME: **Endogenous microRNA sponges: evidence and controversy.** *Nature reviews Genetics* 2016, **17**(5):272-283.

10. Liu L, Yue H, Liu Q, Yuan J, Li J, Wei G, Chen X, Lu Y, Guo M, Luo J *et al.*: **LncRNA MT1JP functions as a tumor suppressor by interacting with TIAR to modulate the p53 pathway.** *Oncotarget* 2016, **7**(13):15787-15800.

11. Xu Y, Zhang G, Zou C, Zhang H, Gong Z, Wang W, Ma G, Jiang P, Zhang W: **LncRNA MT1JP Suppresses Gastric Cancer Cell Proliferation and Migration Through MT1JP/MiR-214-3p/RUNX3 Axis.** *Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology* 2018, **46**(6):2445-2459.

12. Zhu D, Zhang X, Lin Y, Liang S, Song Z, Dong C: **MT1JP inhibits tumorigenesis and enhances cisplatin sensitivity of breast cancer cells through competitively binding to miR-24-3p.** *American journal of translational research* 2019, **11**(1):245-256.

13. Zhang Y, Sui R, Chen Y, Liang H, Shi J, Piao H: **Long noncoding RNA MT1JP inhibits proliferation, invasion, and migration while promoting apoptosis of glioma cells through the activation of PTEN/Akt signaling pathway.** *Journal of cellular physiology* 2019, **234**(11):19553-19564.

14. Yu H, Wang S, Zhu H, Rao D: **LncRNA MT1JP functions as a tumor suppressor via regulating miR-214-3p expression in bladder cancer.** *Journal of cellular physiology* 2019.

15. Yin SL, Xiao F, Liu YF, Chen H, Guo GC: **Long non-coding RNA FENDRR restrains the aggressiveness of CRC via regulating miR-18a-5p/ING4 axis.** *Journal of cellular biochemistry* 2019.

16. Zhou L, Li Z, Pan X, Lai Y, Quan J, Zhao L, Xu J, Xu W, Guan X, Li H *et al.*: **Identification of miR-18a-5p as an oncogene and prognostic biomarker in RCC.** *American journal of translational research* 2018, **10**(6):1874-1886.

17. Liang C, Zhang X, Wang HM, Liu XM, Zhang XJ, Zheng B, Qian GR, Ma ZL: **MicroRNA-18a-5p functions as an oncogene by directly targeting IRF2 in lung cancer.** *Cell death & disease* 2017, **8**(5):e2764.

18. Zhang N, Zhang H, Liu Y, Su P, Zhang J, Wang X, Sun M, Chen B, Zhao W, Wang L *et al.*: **SREBP1, targeted by miR-18a-5p, modulates epithelial-mesenchymal transition in breast cancer via forming a co-repressor complex with Snail and HDAC1/2.** *Cell death and differentiation* 2019, **26**(5):843-859.

19. Benkovic SJ, deMaine MM: **Mechanism of action of fructose 1,6-bisphosphatase.** *Advances in enzymology and related areas of molecular biology* 1982, **53**:45-82.

20. Zhao W, Yang S, Chen J, Zhao J, Dong J: **Forced overexpression of FBP1 inhibits proliferation and metastasis in cholangiocarcinoma cells via Wnt/beta-catenin pathway.** *Life sciences* 2018, **210**:224-234.
21. Miyagiwa M, Ichida T, Tokiwa T, Sato J, Sasaki H: A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium. In vitro cellular & developmental biology : journal of the Tissue Culture Association 1989, 25(6):503-510.

22. Enjoji M, Sakai H, Nawata H, Kajiyama K, Tsuneyoshi M: Sarcomatous and adenocarcinoma cell lines from the same nodule of cholangiocarcinoma. In vitro cellular & developmental biology Animal 1997, 33(9):681-683.

23. Huang XY, Ke AW, Shi GM, Ding ZB, Devbhandari RP, Gu FM, Li QL, Dai Z, Zhou J, Fan J: Overexpression of CD151 as an adverse marker for intrahepatic cholangiocarcinoma patients. Cancer 2010, 116(23):5440-5451.

Tables

Table 1. The sequence information of primers used in this study.

| Name               | Sequence (5'-3')                                      |
|--------------------|-------------------------------------------------------|
| MT1JP Forward      | GAAATGGACCCCAAACCTACTC                                 |
| MT1JP Reverse      | GTTCCCACATCAGGCACAGC                                   |
| β-actin Forward    | CACTGTGCCCATCTACGAGG                                   |
| β-actin Reverse    | TAATGTCACGCACGATTCC                                    |
| hsa-miR-18a-5p RT  | GTTGGCTCTGTGTCAGGGTCCGAGGTATTTCACCAGAGCCACCTATCT      |
| 5S RT              | GATTCCACATCAGGCACAGC                                   |
| hsa-miR-18a-5p Forward | TAAGGTGCATCTAGTGAGATAG                                  |
| hsa-miR-18a-5p Reverse   | GCAGGGTCCGAAGGTATTC                                   |
| 5S Forward         | GATCTCGGAAGCTAAGCAGG                                   |
| 5S Reverse         | TGGTGCAAGGGTCCGAAGGTAT                                |

Table 2. Correlation between MT1JP expression and patients’ clinicopathological characteristics
| Variable               | Category                      | No. of cases | MT1JP low expression (n=29) | MT1JP high expression (n=29) | $\chi^2$  | p value |
|------------------------|-------------------------------|--------------|-----------------------------|-----------------------------|---------|---------|
| Age                    | <60                           | 10           | 7                           |                             | 0.74892 | 0.38682 |
|                        | ≥60                           | 19           | 22                          |                             |         |         |
| Sex                    | Male                          | 19           | 24                          |                             | 2.24806 | 0.13378 |
|                        | Female                        | 10           | 5                           |                             |         |         |
| Tumor size             | ≤5 cm                         | 23           | 29                          |                             | 6.69231 | 0.00968** |
|                        | >5 cm                         | 6            | 0                           |                             | 0.27619 | 0.59921 |
| Tumor location         | Intrahepatic/Perihilar        | 16           | 14                          |                             | 0.27619 | 0.59921 |
|                        | Distal                        | 13           | 15                          |                             |         |         |
| Histology differentiation| Well                         | 3            | 0                           |                             | 3.16364 | 0.0753 |
|                        | Moderate/Poor                 | 26           | 29                          |                             |         |         |
| TNM stage              | I-II                          | 20           | 29                          |                             | 10.6531 | 0.0011** |
|                        | III-IV                        | 9            | 0                           |                             |         |         |
| Lymph node metastasis  | Present                       | 18           | 1                           |                             | 22.6208 | 2.00E-06*** |
|                        | Absent                        | 11           | 28                          |                             |         |         |
| Distal metastasis      | Present                       | 1            | 0                           |                             | 1.01754 | 0.3131 |
|                        | Absent                        | 28           | 29                          |                             |         |         |

**Figures**
Figure 1

MT1JP was downregulated in cholangiocarcinoma specimens A. The expression of MT1JP was detected by real-time PCR in cholangiocarcinoma specimens and paired para-carcinoma tissues. B. The expression of miR-18a-5p was examined. C. The correlation between expression of MT1JP and that of miR-18a-5p in cholangiocarcinoma and para-carcinoma tissues was analyzed with Pearson test.
Figure 2

MT1JP inhibited proliferation and promoted apoptosis in cholangiocarcinoma cells A and B. The levels of MT1JP (A) and miR-18a-5p (B) were detected by real-time PCR in several cholangiocarcinoma cell lines. C and D. The MT1JP levels were verified in HCCC-9810 (C) and HUCCT1 (D) cells after overexpression or knockdown. D and E. CCK-8 assay was used for detection of cell viability. F. The PCNA expression levels were detected by western blot after ectopic expression or silencing of MT1JP. (The
western blot bands were cropped from figure S1 and S2.)

G. Flow cytometry was used for cell distribution in each phase. H. The expression levels of several cell cycle proteins were detected. (The western blot bands were cropped from figure S3-S6.) I. Flow cytometry was performed for detection of cell apoptosis. J. The expression levels of several apoptotic proteins were examined after MT1JP overexpression in HCCC-9810 cells. (The western blot bands were cropped from figure S7 and S8.) (*p<0.05, **p<0.01, ***p<0.001, compared with pcDNA3.1 or siRNA NC; the original images of western blot were shown in supplementary figure 1-8)
MT1JP suppressed migration and invasion in cholangiocarcinoma cells A and B. The migratory ability of HCCC-9810 (A) and HUCCT1 (B) after MT1JP overexpression or knockdown was determined by transwell assay. C and D. Transwell assay supplemented with Matrigel was performed for detection of invasion of cholangiocarcinoma cells. (the scale bar represented as 200 μm) (*p<0.05, **p<0.01, compared with pcDNA3.1 or siRNA NC)
Figure 4

MT1JP bound to miR-18a-5p as a sponge and regulated the expression of FBP1. A. The sequence of MT1JP or FBP1-3’UTR bound by miR-18a-5p. B. Dual-luciferase assay was performed to verify the binding between MT1JP and miR-18a-5p. C. The expression level of miR-18a-5p was detected by real-time PCR after overexpression or knockdown of MT1JP. D. Dual-luciferase assay was carried out to confirm the binding between miR-18a-5p and FBP1-3’UTR. E. The expression level of FBP1 was determined in HCCC-9810 and HUCCT1 cells after transfection of miR-18a-5p mimics. (The western blot bands were cropped from figure S9 and S10.) F. The expression level of FBP1 after ectopic expression of MT1JP or/and miR-18a-5p. (The western blot bands were cropped from figure S11.) G. Immunohistochemical staining was used to detect the expression and distribution of FBP1 after ectopic expression or silencing of MT1JP. (the scale bar represented as 50 μm) (*p<0.05, **p<0.01, ***p<0.001, compared with pcDNA3.1, siRNA NC, or mimics NC; the original images of western blot were shown in supplementary figure 9-11)
Figure 5

The effect of MT1JP was attenuated by overexpression of miR-18a-5p or knockdown of FBP1. A. CCK-8 assay was used to measure the cell ability in HCCC-9810 cells after transfection of MT1JP and miR-18a-5p. B. Flow cytometry was used for measurement of apoptosis. C. Transwell assay supplemented with Matrigel was used for cell invade ability detection. D. The cell ability was detected by CCK-8 assay in HCCC-9810 cells after overexpression of MT1JP and knockdown of FBP1. E. The cell apoptosis was
detected by flow cytometry in HCCC-9810 cells. F. The invade ability was determined by transwell assay supplemented with Matrigel. (the scale bar represented as 200 μm) (*p<0.05, **p<0.01, ***p<0.001, compared with MT1JP+mimics NC or MT1JP+siRNA NC)

Figure 6

MT1JP restrained tumorigenesis in nude mice. HCCC-9810 cells stably transfected with MT1JP or control vector were subcutaneously injected into nude mice, and the tumors were isolated after 3 weeks. A. The subcutaneous tumors. B. The tumor volume. C. HE staining was performed to detect the pathological...
changes of tumors. (the scale bar represented as 100 μm) D. TUNEL assay was used to detect cell apoptosis in tumors. E. Immunohistochemical staining was used to detect the expression of Ki-67. F. Immunohistochemical staining was used to detect the expression of FBP1. (the scale bar in D-F represented as 50 μm) G and H. Real-time PCR was performed for measure the expression of MT1JP and miR-18a-5p in tumors. (*p<0.05, **p<0.001, compared with pcDNA3.1)

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- supplementaryfigurelegends.docx
- figureS2.jpg
- figureS4.jpg
- figureS6.jpg
- figureS3.jpg
- ARRIVEGuidelinesChecklist.pdf
- figureS5.jpg
- figureS8.jpg
- figureS1.jpg
- figureS7.jpg
- figureS9.jpg
- figureS10.jpg
- figureS11.jpg